Delayed methotrexate Elimination
Delayed methotrexate elimination in a affected person with main central nervous system lymphoma: A case report
What is thought and goal: Methotrexate (MTX) is a vital agent for the therapy of main central nervous system lymphomas (PCNSL) however must be given in massive doses by intravenous infusions to realize therapeutic concentrations within the cerebrospinal fluid. Nevertheless, co-administration with many medicine could delay the excretion of MTX which can trigger critical antagonistic results if the serum focus exceeds 0.1 µmol/L 72 h after an intravenous infusion.
Case abstract: A 67-year-old Japanese feminine with PCNSL was handled with high-dose MTX-based chemotherapy. The serum MTX focus 72 h post-infusion was 0.153 µmol/L when she was taking levofloxacin (LVFX) however <0.1 µmol/L 72 h after 4 subsequent infusions when she was not taking LVFX. She was given many different medicine however the timing of the quick course of LVFX and the truth that ciprofloxacin additionally delays MTX excretion means that LVFX was the trigger.
What’s new and conclusion: Co-administration of LVFX could delay the excretion of MTX. Due to this fact, serum concentrations of MTX needs to be monitored to assist stop and enhance the administration of probably critical MTX drug-drug interplay.
C6orf218 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810247 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810253 | ABM | 1.0 ug DNA | EUR 379.2 |
C17orf45 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810259 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM86C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810265 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf31 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810271 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf16 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810283 | ABM | 1.0 ug DNA | EUR 379.2 |
C21ORF55 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810289 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ10357 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810295 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810301 | ABM | 1.0 ug DNA | EUR 379.2 |
ARL17 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810307 | ABM | 1.0 ug DNA | EUR 379.2 |
HSPC047 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810313 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810319 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf22 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810325 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA0774 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810331 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810337 | ABM | 1.0 ug DNA | EUR 379.2 |
IL8RA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810343 | ABM | 1.0 ug DNA | EUR 379.2 |
RBM9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810349 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM62B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810355 | ABM | 1.0 ug DNA | EUR 379.2 |
BC013798 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810361 | ABM | 1.0 ug DNA | EUR 379.2 |
RTCD1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810367 | ABM | 1.0 ug DNA | EUR 379.2 |
TTC15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810373 | ABM | 1.0 ug DNA | EUR 379.2 |
RAD51L1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810379 | ABM | 1.0 ug DNA | EUR 379.2 |
TSP50 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810385 | ABM | 1.0 ug DNA | EUR 379.2 |
TMEM22 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810391 | ABM | 1.0 ug DNA | EUR 379.2 |
KTELC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810397 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810403 | ABM | 1.0 ug DNA | EUR 379.2 |
LASS4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810409 | ABM | 1.0 ug DNA | EUR 379.2 |
TMEM49 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810415 | ABM | 1.0 ug DNA | EUR 379.2 |
C2orf24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810421 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf62 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810427 | ABM | 1.0 ug DNA | EUR 379.2 |
JMJD5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810433 | ABM | 1.0 ug DNA | EUR 379.2 |
AKD2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810439 | ABM | 1.0 ug DNA | EUR 379.2 |
WDR8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810445 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC90379 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810451 | ABM | 1.0 ug DNA | EUR 379.2 |
SFRS17A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810457 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ13052 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810463 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf182 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810469 | ABM | 1.0 ug DNA | EUR 379.2 |
HNRPK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810475 | ABM | 1.0 ug DNA | EUR 379.2 |
C20ORF158 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810481 | ABM | 1.0 ug DNA | EUR 379.2 |
PCTK1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810487 | ABM | 1.0 ug DNA | EUR 379.2 |
IGHGA1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810493 | ABM | 1.0 ug DNA | EUR 379.2 |
C8orf41 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810499 | ABM | 1.0 ug DNA | EUR 379.2 |
C19orf61 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810505 | ABM | 1.0 ug DNA | EUR 379.2 |
C10orf33 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810511 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA1434 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810517 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC23117 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810523 | ABM | 1.0 ug DNA | EUR 379.2 |
C2orf67 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810529 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC10814 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810535 | ABM | 1.0 ug DNA | EUR 379.2 |
BC006419 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810541 | ABM | 1.0 ug DNA | EUR 379.2 |
C21orf122 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810547 | ABM | 1.0 ug DNA | EUR 379.2 |
BC007926 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810553 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ38668 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810559 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC13008 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810565 | ABM | 1.0 ug DNA | EUR 379.2 |
C12orf62 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810571 | ABM | 1.0 ug DNA | EUR 379.2 |
BC001867 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810577 | ABM | 1.0 ug DNA | EUR 379.2 |
Sep15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810583 | ABM | 1.0 ug DNA | EUR 379.2 |
C14orf147 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810589 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC12966 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810595 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC113386 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810601 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC80154 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810607 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC100132167 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810613 | ABM | 1.0 ug DNA | EUR 379.2 |
C4orf42 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810619 | ABM | 1.0 ug DNA | EUR 379.2 |
Selk Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810625 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC21881 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810631 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC13057 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810637 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf20 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810643 | ABM | 1.0 ug DNA | EUR 379.2 |
CXorf50B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810649 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf36 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810655 | ABM | 1.0 ug DNA | EUR 379.2 |
NDR1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810661 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf30 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810667 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf30 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810673 | ABM | 1.0 ug DNA | EUR 379.2 |
Magmas Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810679 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf168 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810685 | ABM | 1.0 ug DNA | EUR 379.2 |
Dram Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810691 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ20897 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810697 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ14107 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810703 | ABM | 1.0 ug DNA | EUR 379.2 |
ZD52F10 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810709 | ABM | 1.0 ug DNA | EUR 379.2 |
SEDLP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810715 | ABM | 1.0 ug DNA | EUR 379.2 |
C14orf48 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810721 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf35 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810727 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC34034 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810733 | ABM | 1.0 ug DNA | EUR 379.2 |
C15ORF15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810739 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC339047 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810745 | ABM | 1.0 ug DNA | EUR 379.2 |
MGC31957 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810751 | ABM | 1.0 ug DNA | EUR 379.2 |
LOC153328 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810757 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf34 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810763 | ABM | 1.0 ug DNA | EUR 379.2 |
RANGNRF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810769 | ABM | 1.0 ug DNA | EUR 379.2 |
RANGNRF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810775 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf10 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810781 | ABM | 1.0 ug DNA | EUR 379.2 |
NAT13 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810787 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf61 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810793 | ABM | 1.0 ug DNA | EUR 379.2 |
FKSG24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810799 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf60 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810805 | ABM | 1.0 ug DNA | EUR 379.2 |
C2orf7 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810811 | ABM | 1.0 ug DNA | EUR 379.2 |
RWDD4A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810817 | ABM | 1.0 ug DNA | EUR 379.2 |
SAPS3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810823 | ABM | 1.0 ug DNA | EUR 379.2 |
Hdgfrp3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810829 | ABM | 1.0 ug DNA | EUR 379.2 |
MOBKL2B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810841 | ABM | 1.0 ug DNA | EUR 379.2 |
RAB39 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810847 | ABM | 1.0 ug DNA | EUR 379.2 |
C10orf58 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810853 | ABM | 1.0 ug DNA | EUR 379.2 |
PI31 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810859 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf142 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810865 | ABM | 1.0 ug DNA | EUR 379.2 |
VPS24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810871 | ABM | 1.0 ug DNA | EUR 379.2 |
AK3L1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810877 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ25770 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810883 | ABM | 1.0 ug DNA | EUR 379.2 |
BC008939 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810889 | ABM | 1.0 ug DNA | EUR 379.2 |
GPR175 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810895 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf190 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810901 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf12 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810907 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf55 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810913 | ABM | 1.0 ug DNA | EUR 379.2 |
SFRS1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810919 | ABM | 1.0 ug DNA | EUR 379.2 |
ZNF509 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810925 | ABM | 1.0 ug DNA | EUR 379.2 |
FRAG1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810931 | ABM | 1.0 ug DNA | EUR 379.2 |
Nip30 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810937 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810943 | ABM | 1.0 ug DNA | EUR 379.2 |
PLUNC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810949 | ABM | 1.0 ug DNA | EUR 379.2 |
UNC84A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810955 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf39 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810961 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf89 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810967 | ABM | 1.0 ug DNA | EUR 379.2 |
Seli Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810973 | ABM | 1.0 ug DNA | EUR 379.2 |
TINP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810979 | ABM | 1.0 ug DNA | EUR 379.2 |
SRrp35 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810985 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf71 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810991 | ABM | 1.0 ug DNA | EUR 379.2 |
HEL308 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810997 | ABM | 1.0 ug DNA | EUR 379.2 |
WDR42A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811003 | ABM | 1.0 ug DNA | EUR 379.2 |
C12orf24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811009 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf30 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811015 | ABM | 1.0 ug DNA | EUR 379.2 |
DIMT1L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811021 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM164C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811027 | ABM | 1.0 ug DNA | EUR 379.2 |
CCDC5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811033 | ABM | 1.0 ug DNA | EUR 379.2 |
C14orf104 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811039 | ABM | 1.0 ug DNA | EUR 379.2 |
MUDENG Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811045 | ABM | 1.0 ug DNA | EUR 379.2 |
Sc4mol Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811051 | ABM | 1.0 ug DNA | EUR 379.2 |
HNRPC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811057 | ABM | 1.0 ug DNA | EUR 379.2 |
HNRPC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811063 | ABM | 1.0 ug DNA | EUR 379.2 |
MCART1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811069 | ABM | 1.0 ug DNA | EUR 379.2 |
CDC2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811075 | ABM | 1.0 ug DNA | EUR 379.2 |
C5orf35 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811081 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf102 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811087 | ABM | 1.0 ug DNA | EUR 379.2 |
SGEF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811093 | ABM | 1.0 ug DNA | EUR 379.2 |
SUNC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811099 | ABM | 1.0 ug DNA | EUR 379.2 |
HNRPA0 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811105 | ABM | 1.0 ug DNA | EUR 379.2 |
TADA2L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811111 | ABM | 1.0 ug DNA | EUR 379.2 |
PXMP3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811117 | ABM | 1.0 ug DNA | EUR 379.2 |
PB1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811123 | ABM | 1.0 ug DNA | EUR 379.2 |
HNRPC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811129 | ABM | 1.0 ug DNA | EUR 379.2 |
AKR1CL2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811135 | ABM | 1.0 ug DNA | EUR 379.2 |
GPSN2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811141 | ABM | 1.0 ug DNA | EUR 379.2 |
NARG1L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811147 | ABM | 1.0 ug DNA | EUR 379.2 |
SCYE1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811153 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ11151 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811159 | ABM | 1.0 ug DNA | EUR 379.2 |
MORG1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811165 | ABM | 1.0 ug DNA | EUR 379.2 |
Perld1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811171 | ABM | 1.0 ug DNA | EUR 379.2 |
JTV1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811177 | ABM | 1.0 ug DNA | EUR 379.2 |
RICS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811183 | ABM | 1.0 ug DNA | EUR 379.2 |
CDC2L5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811189 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM164A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811195 | ABM | 1.0 ug DNA | EUR 379.2 |
GBL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811201 | ABM | 1.0 ug DNA | EUR 379.2 |
RAD51L3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811207 | ABM | 1.0 ug DNA | EUR 379.2 |
C19orf62 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811213 | ABM | 1.0 ug DNA | EUR 379.2 |
BC011600 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811219 | ABM | 1.0 ug DNA | EUR 379.2 |
MOSC2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811225 | ABM | 1.0 ug DNA | EUR 379.2 |
NARG1L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811231 | ABM | 1.0 ug DNA | EUR 379.2 |
TADA1L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811237 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA0174 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811243 | ABM | 1.0 ug DNA | EUR 379.2 |
WDR68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811249 | ABM | 1.0 ug DNA | EUR 379.2 |
SFRS6 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811255 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ23049 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811261 | ABM | 1.0 ug DNA | EUR 379.2 |
CCDC109A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811267 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM29A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811273 | ABM | 1.0 ug DNA | EUR 379.2 |
BC033514 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811279 | ABM | 1.0 ug DNA | EUR 379.2 |
CCDC123 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811285 | ABM | 1.0 ug DNA | EUR 379.2 |
BAT4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811291 | ABM | 1.0 ug DNA | EUR 379.2 |
BC035694 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811297 | ABM | 1.0 ug DNA | EUR 379.2 |
PECI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811303 | ABM | 1.0 ug DNA | EUR 379.2 |
A case report of secondary bilateral orbital lymphoma in a toddler
Lymphoma is without doubt one of the most typical cancers of the orbital and lacrimal glands, after squamous cell carcinoma and melanoma. Based mostly on cell origin, most lymphoma circumstances are categorized as non-Hodgkin lymphoma. Orbital lymphoma may be both main or secondary. The scientific manifestations of lymphoma are various, with the most typical signs being bilateral or unilateral proptosis, restricted eye motility, swelling, ache, adjustments in visible acuity, and diplopia. On this article, we describe the case of a 6-year-old male who offered with bilateral fast orbital swelling for 10 days. This affected person underwent surgical biopsy, and the ultimate prognosis was bilateral orbital secondary non-Hodgkin lymphoma.
Therapy patterns and outcomes of older sufferers with mantle cell lymphoma in an Asian inhabitants
Background: Important progress has been made within the therapy outcomes of mantle cell lymphoma (MCL) for the reason that introduction of cytarabine and rituximab in fashionable regimens. Nevertheless, older sufferers could not readily tolerate these brokers nor derive profit. We investigated the affect of age on therapy patterns and scientific outcomes of MCL sufferers in an Asian inhabitants.
Strategies: A retrospective research was carried out on sufferers (n = 66) identified with MCL on the Nationwide Most cancers Centre Singapore between 1998 and 2018. The median follow-up length was 40 months. Survival analyses have been carried out utilizing the Kaplan-Meier methodology and multivariate Cox proportional fashions.
Outcomes: The median age of the cohort was 59 years (vary, 26-84), with a male predominance (73%). The bulk (86%) had superior stage 3-Four illness at prognosis. In contrast with youthful sufferers, older sufferers aged ≥60 years (n = 32; 48.5%) offered extra incessantly with B-symptoms (75% vs 38%, p = 0.0028), anaemia (75% vs 35%, p = 0.0013), and carried greater prognostic danger scores (sMIPI excessive danger 84% vs 56%, p = 0.016). Non-cytarabine-based induction chemotherapy was extra generally administered in older sufferers (76% vs 32%, p = 0.0012). The 5-year total survival (OS) and progression-free survival (PFS) was 68 and 25% respectively. In a multivariable mannequin, older age (HR 3.42, 95%CI 1.48-7.92, p = 0.004) and anemia (HR 2.56, 95%CI 1.10-5.96, p = 0.029) have been independently related to poorer OS whereas older age (HR 2.24, 95%CI 1.21-4.14, p = 0.010) and hypoalbuminemia (HR 2.20, 95%CI 1.17-4.13, p = 0.014) have been independently related to poorer PFS. In an exploratory evaluation, upkeep rituximab following induction chemotherapy improved PFS in youthful sufferers, with median PFS of 131 months and 45 months with or with out upkeep remedy respectively (HR 0.39, 95%CI 0.16-0.93, p = 0.035). In distinction, no survival profit was noticed in older sufferers.
Conclusions: We demonstrated in our evaluation that older sufferers with MCL could harbor antagonistic scientific options and should not derive profit from upkeep rituximab, highlighting the necessity for additional analysis on this space of want.
Utility of the Euro Clonality next-generation sequencing-based marker screening method to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma sufferers: first knowledge from the Fondazione Italiana Linfomi MCL0208 trial
Minimal residual illness (MRD) decided by traditional polymerase chain response (PCR) strategies is a robust consequence predictor in mantle cell lymphoma (MCL). Nonetheless, some technical pitfalls can scale back the speed of of molecular markers. Due to this fact, we utilized the EuroClonality-NGS IGH (next-generation sequencing immunoglobulin heavy chain) methodology (beforehand printed in acute lymphoblastic leukaemia) to 20 MCL sufferers enrolled in an Italian section III trial sponsored by Fondazione Italiana Linfomi. Outcomes from this preliminary investigation present that EuroClonality-NGS IGH methodology is possible within the MCL context, detecting a molecular IGH goal in 19/20 investigated circumstances, permitting MRD monitoring additionally in these sufferers missing a molecular marker for classical screening approaches.
The position of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
Mechanisms for late-onset neutropenia (LON) after rituximab therapy are poorly outlined each for non-Hodgkin lymphoma (NHL) and for autoimmune issues. We carried out a case-control evaluation of a potential cohort of 169 evaluable consecutive rituximab-treated NHL sufferers to evaluate cytokines concerned in neutro- and lymphopoiesis (G-CSF, SDF1, BAFF, APRIL) and irritation (CRP) as attainable LON mechanisms. Fifteen sufferers (9%) developed LON (peripheral blood /PB/ absolute neutrophil counts /ANC/ < 0.5 G/L, all with marked depletion of CD20+ B-lymphocytes in bone marrows); they have been in contrast with 20 matched NHL controls with out LON. At begin of LON, considerably greater PB G-CSF and BAFF ranges (P = 0.0004 and 0.006, respectively), in addition to CRP rises have been famous in comparison with controls; these G-CSF and BAFF and most CRP values returned to ranges of the controls in post-LON samples.
G-CSF (however not BAFF) adjustments correlated to CRP rises (however to not ANC ranges). BAFF ranges correlated considerably to absolute monocyte counts and PB massive granular lymphocyte counts (however to not ANC, C-CSF or CRP values). No adjustments of SDF1 or APRIL ranges have been famous. Neither LON circumstances nor controls displayed anti-neutrophil autoantibodies. Collectively, LON in NHL sufferers was timewise associated to transient bursts of blood G-CSF and BAFF concentrations, suggesting that these neutro- and lymphopoiesis progress elements play a task in emergence of rituximab-induced LON, and that irritation could also be a set off for G-CSF manufacturing throughout LON.
